Beijing Haibu Pharmaceutical Technology Co., Ltd. (commonly referred to as HopeLife) is a high-tech enterprise established in 2005, specializing in chemical drug research and development. The company provides one-stop CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services, covering project evaluation, patent design, pre-clinical development, clinical trial practice, and regulatory registration.
HopeLife operates a Beijing-based R&D center, pilot verification centers for APIs and formulations, and a GMP industrial production base. Their expertise spans various therapeutic areas including oncology, CNS (anti-depressant, anti-epileptic, anxiolytic), cardiovascular, digestive, and respiratory systems. The company has been recognized as one of the 'China Top 20 Pharmaceutical R&D Companies' and is a national high-tech enterprise.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2005
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Various (Service provider)
Modalities:Small molecule, ADC
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Domestic and international pharmaceutical companies
COMPETITION
Position:Niche Player
LINKS
Website:hopelife.cn
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Beijing Haibu Pharmaceutical Technology Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Beijing Haibu Pharmaceutical Technology Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.